RACHEL GEORGE: Open Payments
NPI 1003055617 · RIDGELAND, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$503 in 22 payments from 12 companies in 2025. Trend: 2023 $390 · 2024 $1,073 · 2025 $503
Food & beverage: $501Education: $2
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $98 |
| Vifor Pharma, Inc. | 3 | $87 |
| Novartis Pharmaceuticals Corporation | 2 | $64 |
| Fresenius USA Marketing, Inc. | 3 | $63 |
| Calliditas Therapeutics US Inc. | 2 | $52 |
| Ardelyx, Inc. | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
Products named: Veltassa, FARXIGA, Vanrafia, VELPHORO, TARPEYO, IBSRELA, JYNARQUE, ACTHAR.
Industry payments across MS — which companies pay providers there.
